Biotech Company Secures New Patent For Fibro-inflammatory Disease Treatment Candidate

Chemomab Earns New Patents for CM-101, Pioneering Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In an exciting development in the world of biotechnology, Chemomab Therapeutics Ltd. (Nasdaq: CMMB), has been granted new patents for CM-101, its first-in-class monoclonal antibody. The patents solidify Chemom…